Lin BioScience, Inc. (6696)
TWSE
Closed
Oct 8, 2026
Day's Range
172.5052 wk Range
18.35Overview - 6696 - Lin BioScience, Inc.
Key Statistics
Valuation
Enterprise Value
140.67B
P/E (Trailing)
‪-108.13‬
Price / Book
‪14.09‬
EV / EBITDA
‪-35.50‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-15.72%‬
Return on Equity
‪-21.83%‬
Ownership
Shares Outstanding
829.20M
Float
637.24M
Held by Insiders
‪0.00%‬
Held by Institutions
‪0.07%‬
Price stats
Beta
‪-0.24‬
50-Day Avg
‪124.66‬
200-Day Avg
‪62.94‬
Market Cap - 6696 - Lin BioScience, Inc.
Peers - 6696 - Lin BioScience, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on TWSE.
- 6696TWSELin BioScience, Inc.149.25BMarket Cap+89.39%52-week change-108.13P/E (Trailing)‪0.00%‬Profit Margin
- 6949TWSEPell Bio-Med Technology Co., Ltd.61.22BMarket Cap-732.98%52-week change-6.49P/E (Trailing)‪-13.97%‬Profit Margin
- 6919TWSECaliway Biopharmaceuticals Co., Ltd.42.55BMarket Cap—52-week change-155.08P/E (Trailing)‪70.55%‬Profit Margin
- 6586TWSECho Pharma Inc.24.82BMarket Cap+68.19%52-week change-85.29P/E (Trailing)‪74.49%‬Profit Margin
- 4743TWSEOneness Biotech Co., Ltd.23.61BMarket Cap-25.89%52-week change370.00P/E (Trailing)‪39.54%‬Profit Margin
- 4728TWSESunmax Biotechnology Co., Ltd.21.48BMarket Cap+0.38%52-week change26.53P/E (Trailing)‪36.97%‬Profit Margin
- 6547TWSEMedigen Vaccine Biologics Corporation20.38BMarket Cap+39.76%52-week change-72.21P/E (Trailing)‪-29.06%‬Profit Margin
Profile Summary - 6696 - Lin BioScience, Inc.
About
Lin BioScience, Inc. is a clinical-stage biotechnology company headquartered in Taipei, Taiwan, focused on the research and development of innovative pharmaceuticals that address diseases with significant unmet medical needs. Founded in 2016, the company operates primarily within the healthcare sector, targeting areas…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
